Dana Flanders

As part of its outlook for biopharma companies in 2021, Guggenheim Securities turned bullish on Amneal Pharmaceuticals Inc (NYSE: AMRX). The Amneal Analyst: Dana Flanders upgraded Amneal from Neutral to Buy with a $5.50 price target.  The Amneal Thesis: Revenue and margin...

The biotech sector has seen some year-to-date strength, as reflected by the nearly 11-percent advance in the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB). The upward momentum became more pronounced in late June. Against this backdrop, a Goldman Sachs analyst is recommending a...

Before Tuesday, 90 percent of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) analysts were buying the stock. But one analyst has diluted the decisive bullishness with rare ambivalence. The Rating Goldman Sachs analyst Dana Flanders initiated coverage on Alder with a Neutral rating and $17 price...

Revance Therapeutics Inc (NASDAQ: RVNC) has dropped 9 percent since the start of the year, but it's begun a path to redemption through a new, respected advocate. The Rating Goldman Sachs analysts Dana Flanders and Christopher Staral initiated coverage on Revance with a Buy rating and a $60...

Investors are hard pressed to find a standout in the specialty pharmaceutical space as many companies lack the "positive narrative" that can be found the rest of the biopharmaceutical space, analysts at Goldman Sachs said in an industry-wide report. The Analyst Goldman Sachs' Dana...

Odonate Therapeutics Inc (NASDAQ: ODT) is a late-stage biopharmaceutical company focused on the treatment of HER2-/HR+ metastatic breast cancer. Most recently, the company began a Phase 3 study of its tesetaxel therapy Contessa. The Analyst Goldman Sachs' Dana Flanders initiated coverage...